Drug name - Jakafi
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(5 years from now) | |
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(5 years from now) | |
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| CN101448826A | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Mar, 2013
(9 years ago) | |
| CN103254190B | INCYTE CORP | Two Surfaces Of Heteroaryl Janus Kinases Inhibitors Substituted Pyrrolo [2 3-B] Pyridine And Pyrrolo [2 3-B] Pyrimidine |
Dec, 2026
(4 years from now) | |
| CN103214484A | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| CN103214483A | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| CN103254190A | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| CN103214483B | INCYTE CORP | Heteroaryl Two Surface Kinase Inhibitor Substituted Pyrrolo [2 3-B] Pyridine And Pyrrolo [2 3-B] Pyrimidine |
Dec, 2026
(4 years from now) | |
| CN103214484B | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| CN103524509A | INCYTE CORP | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| CN101932582A | INCYTE CORP | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| CN101932582B | INCYTE CORP | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| CN103524509B | INCYTE CORP | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| IN269841B | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| IN200802365P2 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP3070090A1 | INCYTE CORP | Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile |
Aug, 2021
(1 year, 1 month ago) | |
| EP3070090B1 | INCYTE CORP | Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile |
Aug, 2021
(1 year, 1 month ago) | |
| EP3466953B1 | INCYTE CORP | Pyrrolo[2,3-D]Pyrimidine Derivative As Janus Kinase Inhibitor |
Dec, 2026
(4 years from now) | |
| EP2343298A1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2343299A1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2343299B1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2348023B9 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2474545A1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2426129B1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2348023B1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP3466953A1 | INCYTE CORP | Pyrrolo[2,3-D]Pyrimidine Derivative As Janus Kinase Inhibitor |
Dec, 2026
(4 years from now) | |
| EP2426129A1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2343298B9 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2474545B1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2343298B1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP3184526B1 | INCYTE CORP | Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor |
Dec, 2026
(4 years from now) | |
| EP2348023A1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2343299B9 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP3184526A1 | INCYTE CORP | Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor |
Dec, 2026
(4 years from now) | |
| EP2455382B1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP2455382A1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(4 years from now) | |
| EP1966202A1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Aug, 2027
(4 years from now) | |
| EP1966202B1 | INCYTE CORP | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Aug, 2027
(4 years from now) | |
| EP2173752A2 | INCYTE CORP | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| EP2173752B2 | INCYTE CORP | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| EP2740731B1 | INCYTE CORP | Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| EP3495369A1 | INCYTE CORP | Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| EP2173752B1 | INCYTE CORP | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| EP2740731A1 | INCYTE CORP | Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| EP3495369B1 | INCYTE CORP | Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9814722 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(4 years from now) | |
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(4 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; For the treatment of polycythemia vera; for the treatment of intermediate or high-risk myelofibrosis; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | TABLET;ORAL | Prescription |
| EQ 10MG BASE | TABLET;ORAL | Prescription |
| EQ 15MG BASE | TABLET;ORAL | Prescription |
| EQ 20MG BASE | TABLET;ORAL | Prescription |
| EQ 25MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.